Dementia with Diabetes Market

Key Highlights

• As per DelveInsight, the Dementia with Diabetes Market is expected to expand at a healthy growth rate during the forecast period (2023-2032), owing to the launch of new therapies in the market and the rise in the number of cases. 
• Several major pharma and biotech companies such as Novo Nordisk, vTv Therapeutics, among others, are actively working in the Dementia with Diabetes Market.

Download the Sample PDF to Get More Insight @ Dementia with Diabetes Market

DelveInsight's "Dementia with Diabetes Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Dementia with Diabetes, historical and forecasted epidemiology as well as the Dementia with Diabetes market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Dementia with Diabetes market report provides current treatment practices, emerging drugs, Dementia with Diabetes market share of the individual therapies, current and forecasted Dementia with Diabetes market size from 2019 to 2032 segmented by seven major markets. The Report also covers current Dementia with Diabetes treatment practices/algorithms, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Dementia with Diabetes market.

Geography Covered

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2019-2032

Dementia co-occurring with diabetes commonly denotes a situation in which an individual grapples with the challenges of both dementia and diabetes concurrently. Dementia, a multifaceted and advancing neurological condition, is typified by a gradual deterioration of cognitive functions, to the extent that it significantly hampers everyday functioning. This dual diagnosis not only compounds the complexity of care but also necessitates a comprehensive and integrated approach to address the unique needs of individuals facing the intricate intersection of these two conditions.

Alzheimer's disease (AD) and vascular dementia (VaD) stand as the predominant dementia disorders, encompassing 60% and 20% of diagnosed cases, respectively. However, the realm of dementia extends beyond these prevalent forms, with other less common but equally impactful conditions. These include Lewy body dementia, frontotemporal dementia, Parkinson's disease dementia (PDD), and instances of mixed dementia, which collectively shape the diverse landscape of neurocognitive disorders. A comprehensive understanding of these variations is crucial in addressing the unique challenges and caregiving considerations they present.

In contrast, diabetes is a persistent metabolic condition marked by elevated blood sugar levels, stemming from either inadequate insulin production or the body's inability to use insulin efficiently. Notably, type 2 diabetes has emerged as a significant risk factor associated with the onset of various cognitive disorders. These encompass not only vascular dementia (VaD), mixed dementia, Alzheimer's disease, and mild cognitive impairment (MCI) but also several other conditions, emphasizing the intricate interplay between metabolic health and cognitive well-being. Understanding this relationship is paramount in comprehending the broader spectrum of cognitive disorders and their potential connections to diabetes.

Individuals diagnosed with Type 1 diabetes face an elevated risk of dementia compared to those without diabetes. Furthermore, for those living with Type 2 diabetes, there is a notable acceleration in cognitive decline, particularly affecting executive function and information-processing speed. This cognitive aspect of diabetes presents a significant concern, primarily affecting the elderly population and carrying substantial implications for public health and the overall quality of life for affected individuals. Recognizing these cognitive risks is paramount for comprehensive diabetes care and underscores the importance of addressing both metabolic and cognitive well-being in diabetes management.

Currently, dementia with diabetes presents a challenging medical scenario for which there is no cure or officially sanctioned treatment. The existing treatment approaches encompass non-insulin therapies like thiazolidinediones, meglitinides, and dipeptidyl peptidase-4 inhibitors, as well as insulin therapy. While insulin therapy stands as the optimal choice for effectively managing blood sugar levels in diabetes patients, its applicability in individuals simultaneously dealing with dementia requires a meticulous and individualized evaluation. With the prevalence of both diabetes and dementia on the rapid rise, it is imperative to invest substantial time and consideration into averting uncontrolled diabetes in this demographic. Despite the array of therapeutic options available, it is crucial to acknowledge the limited efficacy of these treatments for individuals facing the dual challenge of diabetes and dementia.

Dementia with Diabetes Epidemiology 

The Dementia with Diabetes epidemiology section provides insights about the historical and current Dementia with Diabetes patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Dementia with Diabetes market report also provides the diagnosed patient pool and their trends along with assumptions undertaken. 

The disease epidemiology covered in the report provides historical as well as forecasted Dementia with Diabetes epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.

Key Findings

• Alzheimer’s disease is the most common type of dementia. Current estimates are that about 5.8 million people in the United States have Alzheimer’s disease and related dementias, including 5.6 million aged 65 and older and about 200,000 under age 65 with younger-onset Alzheimer’s (CDC, 2022).
• As per the study by Walters & Ikram (2019), vascular dementia is generally considered the second most common subtype of dementia, after Alzheimer disease, accounting for roughly 15% to 20% of dementia cases in North America and Europe.
• According to TREND-UK (2020), the prevalence of Type 2 diabetes and dementia increases in older people and both conditions are significantly increasing in numbers, with over 850,000 people with dementia and almost 3.7 million people with diabetes in the UK.
• As per the study by Takashi Ashada (2017), the survey of early-onset dementia was done in five prefectures and two cities in all parts of Japan from 2006 to 2008. The estimated number of patients per 100,000 in the 18–64-year-old population was 47.6.

Country Wise- Dementia with Diabetes Epidemiology

The epidemiology segment also provides the Dementia with Diabetes epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

The Report Covers the Dementia with Diabetes Epidemiology Segmented as:

• Diagnosed Prevalent Cases of Dementia 
• Age-specific Cases of Dementia
• Type-specific Cases of Dementia
• Treated Cases of Dementia With Diabetes
• Diagnosed Prevalent Cases of Dementia With Diabetes

Get detailed insights into the historical as well as forecasted epidemiology trends in the 7MM, at: Dementia with Diabetes Epidemiology Forecast

Dementia with Diabetes Drug Chapters

The drug chapter segment of the Dementia with Diabetes report encloses the detailed analysis of Dementia with Diabetes marketed drugs and late-stage (Phase-III and Phase-II) Dementia with Diabetes pipeline drugs. It also helps to understand the Dementia with Diabetes clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Dementia with Diabetes Marketed Drugs

The report provides the details of the marketed products/off-label treatments available for Dementia with Diabetes treatment.

Dementia with Diabetes Emerging Drugs

The report provides the details of the emerging therapies under the late and mid-stage of development for Dementia with Diabetes treatment.

Dementia with Diabetes Market Outlook

The Dementia with Diabetes market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Dementia with Diabetes market trends by analyzing the impact of current Dementia with Diabetes therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

This segment gives a thorough detail of Dementia with Diabetes market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Dementia with Diabetes market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Dementia with Diabetes market in 7MM is expected to witness a major change in the study period 2019-2032.

Key Findings

This section includes a glimpse of the Dementia with Diabetes market in 7MM.

The United States Market Outlook

This section provides the total Dementia with Diabetes market size and market size by therapies in the United States.

EU-5 Countries: Market Outlook

The total Dementia with Diabetes market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.

Japan Market Outlook

The total Dementia with Diabetes market size and market size by therapies in Japan is also mentioned.

Dementia with Diabetes Drugs Uptake

This section focuses on the rate of uptake of the Dementia with Diabetes drugs recently launched in the Dementia with Diabetes market or expected to get launched in the market during the study period 2019-2032. The analysis covers Dementia with Diabetes market uptake by drugs; patient uptake by therapies; and sales of each drug.   

Dementia with Diabetes Drugs Uptake helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allow the comparison of the drugs on the basis of Dementia with Diabetes market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Dementia with Diabetes Pipeline Development Activities

The Dementia with Diabetes report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Dementia with Diabetes key players involved in developing targeted therapeutics.

Pipeline Development Activities

The Dementia with Diabetes report covers the detailed information of collaborations, acquisition, and merger, licensing, patent details, and other information for Dementia with Diabetes emerging therapies.

Explore more about the emerging therapies and key companies actively working in the market: Dementia with Diabetes Pipeline Insight

Dementia with Diabetes Market Dynamics and Key Companies in the Market

There is no cure or approved pharmacological therapy for patients suffering from dementia with diabetes. Extensive research and development in this field are needed to bring novel therapies that can improve the treatment landscape and enhance the quality of life for individuals with this condition.

The expansion of the market size can be directly attributed to the rising number of individuals with diabetes and the growing geriatric population affected by dementia across the seven major markets (7MM). Additionally, the introduction of new therapies into the market further propels this growth, as it addresses the evolving healthcare needs and offers hope for improved patient outcomes. Some of the key companies such as Novo Nordisk, vTv Therapeutics, and others are actively working in the Dementia with Diabetes therapeutics market.

Reimbursement Scenario in Dementia with Diabetes

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL- Views

To keep up with current Dementia with Diabetes market trends, we take KOLs and SMEs ' opinion working in the Dementia with Diabetes domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Dementia with Diabetes market trends. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Dementia with Diabetes Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

• The report covers the descriptive overview of Dementia with Diabetes, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
• Comprehensive insight has been provided into the Dementia with Diabetes epidemiology and treatment in the 7MM
• Additionally, an all-inclusive account of both the current and emerging therapies for Dementia with Diabetes is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
• A detailed review of the Dementia with Diabetes market; historical and forecasted is included in the report, covering drug outreach in the 7MM
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Dementia with Diabetes market

Report Highlights

• In the coming years, the Dementia with Diabetes market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
• The companies and academics are working to assess challenges and seek opportunities that could influence Dementia with Diabetes R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition      
• Major players are involved in developing therapies for Dementia with Diabetes. The launch of emerging therapies will significantly impact the Dementia with Diabetes market
• A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Dementia with Diabetes
• Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Dementia with Diabetes Market Report Insights

• Dementia with Diabetes Patient Population
• Dementia with Diabetes Therapeutic Approaches
• Dementia with Diabetes Pipeline Analysis
• Dementia with Diabetes Market Size and Trends
• Dementia with Diabetes Market Opportunities
• Impact of upcoming Dementia with Diabetes Therapies

Dementia with Diabetes Market Report Key Strengths

• 11 Years Forecast
• 7MM Coverage
• Dementia with Diabetes Epidemiology Segmentation
• Key Cross Competition in the Dementia with Diabetes Market
• Highly Analyzed Dementia with Diabetes Market
• Dementia with Diabetes Drugs Uptake

Dementia with Diabetes Market Report Assessment

• Current Dementia with Diabetes Treatment Practices
• Dementia with Diabetes Unmet Needs
• Dementia with Diabetes Pipeline Product Profiles
• Dementia with Diabetes Market Attractiveness
• Dementia with Diabetes Market Drivers and Barriers

Key Questions

Market Insights:

• What was the Dementia with Diabetes drug class share (%) distribution in 2019 and how it would look like in 2032?
• What would be the Dementia with Diabetes total market size as well as market size by therapies across the 7MM during the forecast period (2019-2032)?
• What are the key findings pertaining to the market across 7MM and which country will have the largest Dementia with Diabetes market size during the forecast period (2019-2032)?
• At what CAGR, the Dementia with Diabetes market is expected to grow by 7MM during the forecast period (2019-2032)?
• What would be the Dementia with Diabetes market outlook across the 7MM during the forecast period (2019-2032)?
• What would be the Dementia with Diabetes market growth till 2032, and what will be the resultant market Size in the year 2032?
• How would the unmet needs affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

• What are the disease risk, burden, and regional/ethnic differences of the Dementia with Diabetes?
• What are the key factors driving the epidemiology trend for seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What is the historical Dementia with Diabetes patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What would be the forecasted patient pool of Dementia with Diabetes in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• Where will be the growth opportunities in the 7MM with respect to the patient population pertaining to Dementia with Diabetes?
• Out of all 7MM countries, which country would have the highest prevalent population of Dementia with Diabetes during the forecast period (2019-2032)?
• At what CAGR the patient population is expected to grow in 7MM during the forecast period (2019-2032)?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current options for the Dementia with Diabetes treatment in addition to the approved therapies?
• What are the current treatment guidelines for the treatment of Dementia with Diabetes in the USA, Europe, and Japan?
• What are the Dementia with Diabetes marketed drugs and their respective MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
• How many companies are developing therapies for the treatment of Dementia with Diabetes?
• How many therapies are in-development by each company for Dementia with Diabetes treatment?
• How many are emerging therapies in mid-stage, and late stage of development for Dementia with Diabetes treatment?
• What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Dementia with Diabetes therapies?
• What are the recent novel therapies, targets, mechanisms of action and technologies being developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Dementia with Diabetes and their status?
• What are the current challenges faced in drug development?
• What are the key designations that have been granted for the emerging therapies for Dementia with Diabetes?
• What are the global historical and forecasted market of Dementia with Diabetes?

Reasons to buy

• The report will help in developing business strategies by understanding trends shaping and driving the Dementia with Diabetes market
• To understand the future market competition in the Dementia with Diabetes market and Insightful review of the key market drivers and barriers
• Organize sales and marketing efforts by identifying the best opportunities for Dementia with Diabetes in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
• Organize sales and marketing efforts by identifying the best opportunities for Dementia with Diabetes market
• To understand the future market competition in the Dementia with Diabetes market